Person who experienced the adverse event (patient)
| Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 123445232 | 12344523 | 2 | F | 20150305 | 20160713 | 20160507 | 20160912 | PER | US-JNJFOC-20160403757 | JANSSEN | 74.95 | YR | E | M | Y | 0.00000 | 20160912 | CN | US | US |
Drug(s) used by person
| Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 123445232 | 12344523 | 1 | SS | XARELTO | RIVAROXABAN | 1 | Oral | U | U | UNKNOWN | 0 | 15 | MG | TABLET | QD | ||||
| 123445232 | 12344523 | 2 | SS | XARELTO | RIVAROXABAN | 1 | Oral | U | U | UNKNOWN | 0 | 15 | MG | TABLET | |||||
| 123445232 | 12344523 | 3 | SS | XARELTO | RIVAROXABAN | 1 | Oral | U | U | UNKNOWN | 0 | 15 | MG | TABLET | QD | ||||
| 123445232 | 12344523 | 4 | SS | XARELTO | RIVAROXABAN | 1 | Oral | U | U | UNKNOWN | 0 | 15 | MG | TABLET | |||||
| 123445232 | 12344523 | 5 | SS | XARELTO | RIVAROXABAN | 1 | Oral | U | U | UNKNOWN | 0 | 15 | MG | TABLET | |||||
| 123445232 | 12344523 | 6 | SS | XARELTO | RIVAROXABAN | 1 | Oral | U | U | UNKNOWN | 0 | 15 | MG | TABLET | QD | ||||
| 123445232 | 12344523 | 7 | SS | XARELTO | RIVAROXABAN | 1 | Oral | U | U | UNKNOWN | 0 | 15 | MG | TABLET | QD | ||||
| 123445232 | 12344523 | 8 | PS | XARELTO | RIVAROXABAN | 1 | Oral | U | U | UNKNOWN | 202439 | 15 | MG | TABLET | |||||
| 123445232 | 12344523 | 9 | SS | ASPIRIN. | ASPIRIN | 1 | Oral | U | 0 | 81 | MG | TABLET | QD | ||||||
| 123445232 | 12344523 | 10 | SS | PLAVIX | CLOPIDOGREL BISULFATE | 1 | Oral | U | 0 | 75 | MG | TABLET | QD |
Indications of drugs used
| Event ID | CASEID | INDI DRUG SEQ | INDI PT |
|---|---|---|---|
| 123445232 | 12344523 | 1 | Cardiovascular disorder |
| 123445232 | 12344523 | 2 | Cardiovascular disorder |
| 123445232 | 12344523 | 3 | Cerebrovascular accident prophylaxis |
| 123445232 | 12344523 | 4 | Cerebrovascular accident prophylaxis |
| 123445232 | 12344523 | 5 | Thrombosis prophylaxis |
| 123445232 | 12344523 | 6 | Thrombosis prophylaxis |
| 123445232 | 12344523 | 7 | Atrial fibrillation |
| 123445232 | 12344523 | 8 | Atrial fibrillation |
| 123445232 | 12344523 | 9 | Myocardial infarction |
| 123445232 | 12344523 | 10 | Acute coronary syndrome |
Outcome of event
| Event ID | CASEID | OUTC COD |
|---|---|---|
| 123445232 | 12344523 | HO |
Reactions reported
| Event ID | CASEID | DRUG REC ACT | PT |
|---|---|---|---|
| 123445232 | 12344523 | Epistaxis | |
| 123445232 | 12344523 | Gastrointestinal haemorrhage | |
| 123445232 | 12344523 | Haemorrhoidal haemorrhage |
Reporting Sources (this data is often not reported and may therefore be missing here)
| no results found |
Therapies reported
| Event ID | CASEID | DSG DRUG SEQ | START DT | END DT | DUR | DUR COD |
|---|---|---|---|---|---|---|
| 123445232 | 12344523 | 1 | 20150220 | 20150305 | 0 | |
| 123445232 | 12344523 | 3 | 20150220 | 20150305 | 0 | |
| 123445232 | 12344523 | 6 | 20150220 | 20150305 | 0 | |
| 123445232 | 12344523 | 7 | 20150220 | 20150305 | 0 |